Cargando…

Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study

Mostrar otras versiones (1)

Correction to Geitona M, Kousoulakou H, Ollandezos M, Athanasakis K, Papanicolaou S and Kyriopoulos I: Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study. Annals of General Psychi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Geitona, Maria, Kousoulakou, Hara, Ollandezos, Markos, Athanasakis, Kostas, Papanicolaou, Sotiria, Kyriopoulos, Ioannis
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2705371/ http://dx.doi.org/10.1186/1744-859X-8-15

Ejemplares similares

Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: A cost effectiveness study
por: Geitona, Maria, et al.
Publicado: (2008)

Antibacterial Treatment of Meticillin-Resistant Staphylococcus Aureus Complicated Skin and Soft Tissue Infections: a Cost and Budget Impact Analysis in Greek Hospitals
por: Athanasakis, Kostas, et al.
Publicado: (2014)

Investigating the Value of Abatacept in the Treatment of Rheumatoid Arthritis: A Systematic Review of Cost-Effectiveness Studies
por: Athanasakis, Kostas, et al.
Publicado: (2013)

Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece
por: Einarson, Thomas R, et al.
Publicado: (2012)

Cost-effectiveness of eplerenone in NYHA class II chronic heart failure patients with reduced LVEF: an analysis for Greece
por: Athanasakis, Kostas, et al.
Publicado: (2016)

A Cost-Effectiveness and Budget Impact Analysis of AbobotulinumtoxinA in Greece
por: Nomikos, Nikolaos, et al.
Publicado: (2023)

Barriers in access to healthcare services for chronic patients in times of austerity: an empirical approach in Greece
por: Kyriopoulos, Ilias-Ioannis, et al.
Publicado: (2014)

Dutasteride plus Tamsulosin fixed-dose combination first-line therapy versus Tamsulosin Monotherapy in the treatment of benign prostatic hyperplasia: a budget impact analysis in the Greek healthcare setting
por: Geitona, Maria, et al.
Publicado: (2014)

Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France
por: Druais, Sylvain, et al.
Publicado: (2016)

Subjective social status, social network and health disparities: empirical evidence from Greece
por: Charonis, Antonios, et al.
Publicado: (2017)

Cost–Benefit Analysis of Single versus Repeated Use of Single-Use Devices in Cataract Surgery
por: Naoum, Panagiota, et al.
Publicado: (2021)

Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece
por: Kousoulakou, Hara, et al.
Publicado: (2017)

Estimates of price and income elasticity in Greece. Greek debt crisis transforming cigarettes into a luxury good: an econometric approach
por: Tarantilis, Filippos, et al.
Publicado: (2015)

The direct and indirect costs of managing chronic obstructive pulmonary disease in Greece
por: Souliotis, Kyriakos, et al.
Publicado: (2017)

Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost effectiveness analysis for the Greek healthcare setting
por: Athanasakis, Kostas, et al.
Publicado: (2013)

Cost-effective osteoporosis treatment thresholds for people living with HIV infection in Greece
por: Makras, Polyzois, et al.
Publicado: (2017)

Costs and Resource Utilization Among Medicaid Patients with Schizophrenia Treated with Paliperidone Palmitate or Oral Atypical Antipsychotics
por: Pesa, Jacqueline A., et al.
Publicado: (2015)

Direct and Indirect Costs of Asthma Management in Greece: An Expert Panel Approach
por: Souliotis, Kyriakos, et al.
Publicado: (2017)

Effects of paliperidone extended release on the symptoms and functioning of schizophrenia
por: Huang, Min-Wei, et al.
Publicado: (2012)

Cost-Sharing Rates Increase During Deep Recession: Preliminary Data From Greece
por: Gouvalas, Athanasios, et al.
Publicado: (2016)

The annual direct costs of stable COPD in Greece
por: Stafyla, Eirini, et al.
Publicado: (2018)

Knowledge, Perceptions and Attitudes Toward HPV Vaccination: A Survey on Parents of Girls Aged 11–18 Years Old in Greece
por: Naoum, Panagiota, et al.
Publicado: (2022)

The Influence of Previous Antipsychotic Polypharmacy Versus Monotherapy on the Effectiveness of Antipsychotic after Switching to Paliperidone Extended-release
por: Lee, Hee-Won, et al.
Publicado: (2013)

A cost-utility analysis of Amisulpride and Paliperidone in the treatment of Schizophrenia
por: Abdall-Razak, Ali, et al.
Publicado: (2019)

Cost-utility analysis of using paliperidone palmitate in schizophrenia in China
por: Luo, Rui, et al.
Publicado: (2023)

Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses
por: García-Ruiz, Antonio J, et al.
Publicado: (2012)

Paliperidone extended-release: does it have a place in antipsychotic therapy?
por: Gahr, Maximilian, et al.
Publicado: (2011)

Effects of paliperidone extended release on hostility among Thai patients with schizophrenia
por: Jariyavilas, Apichat, et al.
Publicado: (2017)

EE527 Cost-Effectiveness and Budget Impact Analysis of Remdesivir for the Treatment of COVID-19 in Greece
por: Athanasakis, K, et al.
Publicado: (2022)

Cost of antipsychotic polypharmacy in the treatment of schizophrenia
por: Zhu, Baojin, et al.
Publicado: (2008)

Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication
por: Yang, Fu De, et al.
Publicado: (2017)

HPR118 An Updated Estimate of the Direct Cost of the COVID-19 Pandemic for the Greek Healthcare System
por: Athanasakis, K, et al.
Publicado: (2022)

Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia
por: Turkoz, Ibrahim, et al.
Publicado: (2008)

PNS21 From Disease Burden to Healthcare Cost: Highlighting the Health Economics Aspects of the COVID-19 Pandemic
por: Athanasakis, K., et al.
Publicado: (2020)

Outpatient Antipsychotic Treatment and Inpatient Costs of Schizophrenia
por: Marcus, Steven C., et al.
Publicado: (2008)

Use of Conventional Antipsychotics and the Cost of Treating Schizophrenia
por: Lyu, Ramon R., et al.
Publicado: (2001)

Influencing Factors and Predictors of Early Response in Schizophrenia Patients Receiving the Paliperidone Extended-Release Tablets (Paliperidone ER)
por: Jung, Seung-Ho, et al.
Publicado: (2013)

Safety and Efficacy of Paliperidone Extended-Release in Acute and Maintenance Treatment of Schizophrenia
por: Spina, Edoardo, et al.
Publicado: (2011)

Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US
por: O’Day, Ken, et al.
Publicado: (2013)

Adherence, Persistence, Readmissions, and Costs in Medicaid Members with Schizophrenia or Schizoaffective Disorder Initiating Paliperidone Palmitate Versus Switching Oral Antipsychotics: A Real-World Retrospective Investigation
por: Dickson, Matthew C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j4jpg8tqekrpm8o3om2e9bp2g0